Gisele A Nishiguchi

Title: Gisele A. Nishiguchi: Innovator in Pharmaceutical Modulation

Introduction

Gisele A. Nishiguchi is a prominent inventor based in Memphis, TN (US). She has made significant contributions to the field of pharmaceuticals, particularly in the modulation of proteins associated with various clinical conditions. With a total of 2 patents, her work is paving the way for innovative treatments.

Latest Patents

Gisele's latest patents focus on substituted N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein. These compounds are designed to be useful in treating disorders of uncontrolled cellular proliferation, such as cancer, which may be linked to cereblon protein dysfunction and/or GSPT1 dysfunction. The disclosed compounds can selectively modulate the degradation of GSPT1 protein, acting as GSPT1 degraders. This innovative approach holds promise for developing new therapeutic strategies.

Career Highlights

Gisele A. Nishiguchi is affiliated with St. Jude Children's Research Hospital, where she continues to advance her research in pharmaceutical sciences. Her work is characterized by a commitment to addressing critical health challenges through innovative solutions.

Collaborations

Gisele collaborates with esteemed colleagues, including Fatemeh Keramatnia and Kevin McGowan. These partnerships enhance the research environment and contribute to the development of groundbreaking therapies.

Conclusion

Gisele A. Nishiguchi's contributions to the field of pharmaceuticals exemplify the impact of innovative research on healthcare. Her work in modulating cereblon protein and GSPT1 degradation is a testament to her dedication to improving clinical outcomes.